Infliximab (IFX), an anti-Tumor Necrosis Factor (TNF)-α IgG1-κ chimeric monoclonal antibody, as a representative of the biologics, has significantly altered the treatment of moderate-to-severe CD through the neutralization of the pro-inflammatory effects of TNF-α, induction of mucosal healing, and modulation of immune cell apoptosis [7, 8]. This evidence concerns the gene TNF and Cowden disease.